Carna Biosciences Past Earnings Performance
Past criteria checks 0/6
Carna Biosciences's earnings have been declining at an average annual rate of -32.7%, while the Life Sciences industry saw earnings growing at 25.6% annually. Revenues have been declining at an average rate of 12.5% per year.
Key information
-32.7%
Earnings growth rate
-28.1%
EPS growth rate
| Life Sciences Industry Growth | 32.0% |
| Revenue growth rate | -12.5% |
| Return on equity | -56.9% |
| Net Margin | -107.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Carna Biosciences, Inc. (TSE:4572) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely
Aug 06
What Carna Biosciences, Inc.'s (TSE:4572) P/S Is Not Telling You
Apr 17Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?
Apr 11How Much Did Carna Biosciences'(TYO:4572) Shareholders Earn From Share Price Movements Over The Last Five Years?
Feb 17Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?
Dec 26
Revenue & Expenses Breakdown
How Carna Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,401 | -1,510 | 817 | 1,903 |
| 30 Jun 24 | 1,440 | -1,361 | 711 | 1,903 |
| 31 Mar 24 | 1,579 | -1,031 | 530 | 1,903 |
| 31 Dec 23 | 1,625 | -1,152 | 664 | 1,903 |
| 30 Sep 23 | 1,002 | -1,784 | 667 | 1,882 |
| 30 Jun 23 | 1,047 | -1,875 | 816 | 1,882 |
| 31 Mar 23 | 1,058 | -1,853 | 776 | 1,882 |
| 31 Dec 22 | 1,386 | -1,349 | 603 | 1,882 |
| 30 Sep 22 | 2,476 | -151 | 588 | 1,841 |
| 30 Jun 22 | 2,426 | -117 | 502 | 1,841 |
| 31 Mar 22 | 2,340 | -263 | 600 | 1,841 |
| 31 Dec 21 | 2,017 | -534 | 572 | 1,841 |
| 30 Sep 21 | 922 | -1,640 | 903 | 1,474 |
| 30 Jun 21 | 984 | -1,490 | 788 | 1,474 |
| 31 Mar 21 | 1,029 | -1,213 | 546 | 1,474 |
| 31 Dec 20 | 1,133 | -1,111 | 524 | 1,474 |
| 30 Sep 20 | 1,192 | -934 | 717 | 1,281 |
| 30 Jun 20 | 1,326 | -764 | 696 | 1,281 |
| 31 Mar 20 | 3,373 | 880 | 843 | 1,281 |
| 31 Dec 19 | 3,207 | 828 | 741 | 1,281 |
| 30 Sep 19 | 3,030 | 725 | 692 | 1,140 |
| 30 Jun 19 | 2,815 | 474 | 702 | 1,140 |
| 31 Mar 19 | 712 | -1,252 | 533 | 1,140 |
| 31 Dec 18 | 754 | -1,210 | 508 | 1,140 |
| 30 Sep 18 | 760 | -1,051 | 842 | 670 |
| 30 Jun 18 | 730 | -910 | 683 | 670 |
| 31 Mar 18 | 672 | -813 | 554 | 670 |
| 31 Dec 17 | 657 | -737 | 464 | 670 |
| 30 Sep 17 | 713 | -619 | 535 | 513 |
| 30 Jun 17 | 695 | -572 | 473 | 513 |
| 31 Mar 17 | 782 | -396 | 449 | 513 |
| 31 Dec 16 | 811 | -289 | 468 | 513 |
| 30 Sep 16 | 873 | -294 | 607 | 417 |
| 30 Jun 16 | 877 | -243 | 574 | 417 |
| 31 Mar 16 | 1,460 | 351 | 502 | 417 |
| 31 Dec 15 | 1,569 | 456 | 409 | 417 |
| 30 Sep 15 | 1,428 | 116 | 240 | 561 |
| 30 Jun 15 | 1,439 | 77 | 277 | 561 |
| 31 Mar 15 | 777 | -641 | 364 | 561 |
| 31 Dec 14 | 611 | -846 | 416 | 561 |
| 30 Sep 14 | 671 | -477 | 504 | 423 |
| 30 Jun 14 | 736 | -388 | 481 | 423 |
| 31 Mar 14 | 762 | -322 | 441 | 423 |
| 31 Dec 13 | 771 | -282 | 408 | 423 |
Quality Earnings: 4572 is currently unprofitable.
Growing Profit Margin: 4572 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4572 is unprofitable, and losses have increased over the past 5 years at a rate of 32.7% per year.
Accelerating Growth: Unable to compare 4572's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4572 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-2.3%).
Return on Equity
High ROE: 4572 has a negative Return on Equity (-56.9%), as it is currently unprofitable.